Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.
Journal Information
Full Title: Liver Cancer
Abbreviation: Liver Cancer
Country: Unknown
Publisher: Unknown
Language: N/A
Publication Details
Subject Category: Gastroenterology & Hepatology
Available in Europe PMC: Yes
Available in PMC: Yes
PDF Available: No
Related Papers from Same Journal
Transparency Score
Transparency Indicators
Click on green indicators to view evidence textCore Indicators
"Conflict of Interest Statement Atsushi Hiraoka, MD, PhD: lecture fees; Chugai and Eli Lilly. Takashi Kumada, MD, PhD: lecture fees; Eisai. None of the other authors have potential conflicts of interest to declare. Masatoshi Kudo, MD, PhD − Advisory role: Eiasi, Ono, MSD, Bristol-Myers Squibb, Roche; Lecture fees: Eisai, Bayer, MSD, Bristol-Myers Squibb, Eli Lilly, EA Pharma; Research funding: Gilead Sciences, Taiho, Sumitomo Dainippon Pharma, Takeda, Otsuka, EA Pharma, Abbvie, Eisai. Prof. Kudo is the Editor-in-Chief of Liver Cancer and Dr. Nouso an Editorial Board Member of Liver Cancer. None of the other authors have potential conflicts of interest to declare."
"None to declare."
Additional Indicators
Assessment Info
Tool: rtransparent
OST Version: N/A
Last Updated: Aug 05, 2025